Chronic hypoxia promotes hypoxia-inducible factor-1-α-dependent resistance to etoposide and vincristine in neuroblastoma cells

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2241-2250

  Hussein, Deema ^a   Estlin, Edward J ^b   Dive, Caroline ^a,c   Makin, Guy W J ^a,b,c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; CARBONATE DEHYDRATASE IX; CISPLATIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; PROTEIN BCL 2; SHORT HAIRPIN RNA; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; NEUROBLASTOMA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION;

APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; VINCRISTINE;

EID: 33749556704     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0145     Document Type: Article

References (44)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73.
2. Harris AL. Hypoxia - a key regulatory element in tumour growth. Nat Rev Cancer 2002;2:38-47.
3. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
4. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
5. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
6. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 α by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000;19:4298-309.
7. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
8. Bruick RK. Expression of the gene encoding the pro-apoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A 2000;97:9082-7.
9. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001;61:6669-73.
10. Van de Velde C, Cizeau J, Dubik D, et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2000;20:5454-68.
11. Chen D, Li M, Gu W. Direct interactions between HIF-1 α and Mdm2 modulate p53 function. J Biol Chem 2003;278:13595-8.
12. Rossler J, Schwab M, Havers W, Schweigerer L. Hypoxia promotes apoptosis of human neuroblastoma cell lines with enhanced N-myc expression. Biochem Biophys Res Commun 2001;281:272-6.
13. Erler JT, Cawthorne CJ, Williams KJ, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumours occurs via hypoxia-incducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
14. Jogi A, Ora I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002;99:7021-6.
15. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000;6:1900-8.
16. Yeo E-J, Chun Y-S, Cho Y-S, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
17. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83.
18. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive PL. Reduced expression of hypoxia-inducible factor-1α in peri-necrotic regions of solid tumors. Cancer Res 2005;65:7259-66.
19. Sowter HS, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of death factors BNIP3 and NIX in human tumours. Cancer Res 2001;61:6669-73.
20. Nelson DA, Tan T-T, Rabson AB, Anderson D, Degenhardt K, White E. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 2004;18:2095-107.
21. Koshiji M, To KKW, Hammer S, et al. HIF-1α induces genetic instability by transcriptionally down-regulating MutSα expression. Mol Cell 2005;17:793-803.
22. EL and activation of HIF1. J Cell Biol 2005;168:911-20.
23. Jogi A, Vallon-Christerron J, Holmquist L, Axelson H, Borg A, Pahlman S. Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behaviour. Exp Cell Res 2004;295:469-87.
24. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983;71:741-9.
25. Makin GWJ, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA, Dive C. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. EMBO J 2001;20:6306-15.
26. Brown LM, Cowen RL, Debray C, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 2006;69:411-8.
27. Kalra R, Jones AM, Kirk J, Adams GE, Stratford IJ. The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast cancer cells in vitro. Int J Cancer 1993;19:650-5.
28. Rodriguez-Lopez AM, Xenaki D, Eden OB, Hickman JA, Chresta CM. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol Pharmacol 2001;59:135-43.
29. Das B, Yeger H, Tsuchida R, et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1α through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 2005;65:7267-75.
30. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nature Rev Cancer 2004;4:437-47.
31. Dong Z, Venkatachalam MA, Wang J, et al. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. J Biol Chem 2001;276:18702-9.
32. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1 α is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
33. Wiesener MS, Turley H, Allen WE, et al. Induction of encdothelial PAS domain-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 1998;92:2260-8.
34. Graven KK, Bellur D, Klahn BD, Lowrey SL, Amberger E. HIF-2α regulates glyceraldehyde-3-phosphate dehydrogenase expression in endothelial cells. Biochim Biophys Acta 2003;1626:10-8.
35. Uchida T, Rossignol F, Matthay MA, et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-lα and HIF-2α expression in lung epithelial cells. J Biol Chem 2004; 279:14871-8.
36. Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta 2005;1755:107-20.
37. Chang T-C, Huang C-J, Tam K, et al. Stabilization of hypoxia-inducible factor-1α by prostacyclin under prolonged hypoxia via reducing reactive oxygen species in endothelial cells. J Biol Chem 2005; 280:36567-74.
38. Demidenko ZN, Rapisarda A, Garayoa M, Giannakakou P, Melillo G, Blagosklonny MV. Accumulation of hypoxia-inducible factor-1α is limited by transcription-dependent depletion. Oncogene 2005;24:4829-38.
39. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumours: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
40. Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF1 blockade on tumor radiosensitivity. Cancer Cell 2005;8:99-110.
41. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-incducible factor-1α. Mol Cancer Ther 2004;3:233-44.
42. Chau N-M, Rogers P, Aherne W, et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1α induction in response to hypoxic stress and growth factors. Cancer Res 2005;65:4918-28.
43. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
44. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible pathway. Cancer Cell 2004;6:33-43.